Penn Medicine Abramson Cancer Center

 

Controversies and Update for Patient Care in Multiple Myeloma
17:09

Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient

Should We Treat High-Risk Smoldering Myeloma, Trials with Daratumumab In Frontline & General Approach for Newly Diagnosed Multiple Myeloma

FEATURING Alfred Garfall
  • 559 views
  • February 24, 2020
  • 1
11:50

Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient

Transplant and Maintenance in Frontline Multiple Myeloma: High-dose Melphalan + ASCT & Post-ASCT Lenalidomide Maintenance Prolongs PFS/OS

FEATURING Alfred Garfall
  • 36 views
  • February 24, 2020
21:42

Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient

ASH 2019 Update on New Therapies for Relapsed Myeloma: Daratumumab, Selinexor + Pom/dex & Investigational Combinations With Venetoclax

FEATURING Dan T. Vogl
  • 38 views
  • February 24, 2020
09:09

Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient

ASH 2019 Update on Promising New Agents in R/R Multiple Myeloma: Iberdomide, TAK573, Tasquinimod & Choosing Therapies with Limited Data

FEATURING Dan T. Vogl
  • 19 views
  • February 24, 2020
26:41

Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient

BCMA - Based Immunotherapy for Myeloma: Belantamab Mafodotin, CAR-T Cells & Bispecific Antibodies

FEATURING Adam D. Cohen
  • 288 views
  • February 24, 2020
  • 1
21:58

Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient

Treatment of 57 y/o Women with Myeloma R-ISS Stage 1, Anemia and Lytic Lesions: Choosing Optimal Induction Therapy & Maintenance Therapy

FEATURING Adam D. Cohen, Dan T. Vogl, Alfred Garfall
  • 27 views
  • February 24, 2020